Characterization of the metabolic profile associated with serum 25-hydroxyvitamin D : a cross-sectional analysis in population-based data by Vogt, Susanne et al.
Metabolomics
Characterization of the metabolic profile
associated with serum 25-hydroxyvitamin D: a
cross-sectional analysis in population-based data
Susanne Vogt,1,2† Simone Wahl,1,3,4† Johannes Kettunen,5,6,7
Susanne Breitner,1 Gabi Kastenmu¨ller,8 Christian Gieger,1,3,4
Karsten Suhre,8,9 Melanie Waldenberger,1,3 Ju¨rgen Kratzsch,10
Markus Perola,7,11,12 Veikko Salomaa,7 Stefan Blankenberg,13,14
Tanja Zeller,13,14 Pasi Soininen,5,6 Antti J Kangas,5 Annette Peters,1,2,4
Harald Grallert,1,3,4 Mika Ala-Korpela5,6,15 and Barbara Thorand1,4*
1Institute of Epidemiology II, Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental
Health, Neuherberg, Germany, 2German Center for Cardiovascular Research (DZHK e.V.), Munich
Heart Alliance, Munich, Germany, 3Research Unit of Molecular Epidemiology, Helmholtz Zentrum
Mu¨nchen, German Research Center for Environmental Health, Neuherberg, Germany, 4German Center
for Diabetes Research (DZD e.V.), Mu¨nchen-Neuherberg, Germany, 5Computational Medicine,
University of Oulu and Biocenter Oulu, Oulu, Finland, 6NMR Metabolomics Laboratory, University of
Eastern Finland, Kuopio, Finland, 7National Institute for Health and Welfare, Helsinki, Finland, 8Institute
of Bioinformatics and Systems Biology, Helmholtz Zentrum Mu¨nchen, German Research Center for
Environmental Health, Neuherberg, Germany, 9Department of Physiology and Biophysics, Weill Cornell
Medical College in Qatar, Education City, Doha, Qatar, 10Institute of Laboratory Medicine, Clinical
Chemistry and Molecular Diagnostics, University Leipzig, Leipzig, Germany, 11Institute for Molecular
Medicine (FIMM) and Diabetes and Obesity Research Program, University of Helsinki, Helsinki,
Finland, 12Estonian Genome Center, University of Tartu, Tartu, Estonia, 13University Heart Center
Hamburg, Clinic of General and Interventional Cardiology, Hamburg, Germany, 14German Center for
Cardiovascular Research (DZHK e.V.), Partner Site Hamburg/Lu¨beck/Kiel, Hamburg, Germany and
15Computational Medicine, School of Social and Community Medicine, University of Bristol and
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
†Equal contributors.
*Corresponding author. Helmholtz Zentrum Mu¨nchen, Institute of Epidemiology II, Ingolst€adter Landstraße 1, 85764
Neuherberg, Germany. E-mail: thorand@helmholtz-muenchen.de
Accepted 28 June 2016
Abstract
Background: Numerous observational studies have observed associations between vita-
min D deficiency and cardiometabolic diseases, but these findings might be confounded
by obesity. A characterization of the metabolic profile associated with serum 25-hydroxy-
vitamin D [25(OH)D] levels, in general and stratified by abdominal obesity, may help to
untangle the relationship between vitamin D, obesity and cardiometabolic health.
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Original article
Methods: Serum metabolomics measurements were obtained from a nuclear magnetic
resonance spectroscopy (NMR)- and a mass spectrometry (MS)-based platform. The dis-
covery was conducted in 1726 participants of the population-based KORA-F4 study, in
which the associations of the concentrations of 415 metabolites with 25(OH)D levels
were assessed in linear models. The results were replicated in 6759 participants (NMR)
and 609 (MS) participants, respectively, of the population-based FINRISK 1997 study.
Results:Mean [standard deviation (SD)] 25(OH)D levels were 15.2 (7.5) ng/ml in KORA F4
and 13.8 (5.9) ng/ml in FINRISK 1997; 37 metabolites were associated with 25(OH)D in
KORA F4 at P< 0.05/415. Of these, 30 associations were replicated in FINRISK 1997 at
P<0.05/37. Among these were constituents of (very) large very-low-density lipoprotein
and small low-density lipoprotein subclasses and related measures like serum triglycer-
ides as well as fatty acids and measures reflecting the degree of fatty acid saturation. The
observed associations were independent of waist circumference and generally similar in
abdominally obese and non-obese participants.
Conclusions: Independently of abdominal obesity, higher 25(OH)D levels were associ-
ated with a metabolite profile characterized by lower concentrations of atherogenic lipids
and a higher degree of fatty acid polyunsaturation. These results indicate that the rela-
tionship between vitamin D deficiency and cardiometabolic diseases is unlikely to merely
reflect obesity-related pathomechanisms.
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Background
Vitamin D has traditionally been recognized for its im-
portant role in bone biology,1 but research within the
past two decades has started to focus on potential risks of
vitamin D deficiency beyond skeletal health.2 In order to
carry out its biological functions, vitamin D, which is ei-
ther synthesized in the skin upon exposure to ultraviolet B
radiation or taken up from the diet, is initially converted to
25-hydroxyvitamin D [25(OH)D] in the liver.3 Serum levels
of 25(OH)D, the major circulating vitamin D metabolite,3
are the preferred measure to determine vitamin D status.4 In
a strictly regulated process, 25(OH)D is hydroxylated to
1,25-dihydroxyvitamin D [1,25(OH)2D], the biologically
active vitamin D metabolite, in the kidneys.1 With the ex-
ception of patients with kidney disease,5 oral vitamin D ad-
ministration increases the circulating concentrations of both
1,25(OH)2D and 25(OH)D.
6
Low levels of serum 25(OH)D are common throughout
the European population.7 In Germany, 31% of the adult
participants of the national health survey 2008-11 had inad-
equate levels of serum 25(OH)D (< 20 ng/l), and another
30% were 25(OH)D-deficient (< 12 ng/ml).8 Possible adverse
Key Messages
• We examined the serum metabolite profile associated with serum 25-hydroxyvitamin D levels in metabolites obtained
from both a nuclear magnetic resonance spectroscopy (NMR)- and a mass spectrometry (MS)-based platform.
• The discovery, based on 415 metabolites, was conducted in 1726 participants of the population-based KORA-F4 study.
The results were replicated in 6759 participants (NMR) and 609 (MS) participants, respectively, of the population-
based FINRISK 1997 study.
• In all, 37 metabolites were associated with 25(OH)D in KORA F4 after correction for multiple testing. Of these, 30 as-
sociations were replicated in FINRISK 1997.
• Higher serum 25-hydroxyvitamin D levels were associated with a serum metabolite profile characterized by lower
concentrations of atherogenic lipids and a higher degree of fatty acid polyunsaturation. These associations were inde-
pendent of waist circumference and similarly observed in abdominally obese and non-obese participants.
• Our results indicate that the relationship between vitamin D deficiency and cardiometabolic diseases is unlikely to
merely reflect pathomechanisms related to obesity.
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effects of vitamin D deficiency on non-skeletal health are
thus of considerable public health interest. Meta-analyses
of observational studies have shown an association be-
tween low levels of serum 25(OH)D and a wide array of
chronic diseases, including cardiovascular disease and
type 2 diabetes.2,9 By contrast, findings from randomized
controlled trials so far do not support a beneficial effect
of vitamin D supplementation on cardiometabolic
health.2,9 Previous trials were generally limited by factors
such as inadequate study designs, low doses of vitamin D
and relatively short follow-up periods.10 However, the
discrepancy between observational and intervention stud-
ies on the relationship between vitamin D and cardiome-
tabolic diseases may also result from the former being
affected by residual confounding; 25(OH)D levels are
known to be especially low in obese individuals,11 with
the proportion of subjects with inadequate 25(OH)D lev-
els being about twice as high in obese than in non-obese
persons.12 Since obesity is also associated with type 2 dia-
betes and various cardiovascular diseases,13 a confound-
ing effect by obesity seems relatively likely. However,
associations between 25(OH)D and cardiometabolic risk
factors have also been found in spite of adjustment for
body mass index (BMI).14–16
A better understanding of the biological mechanisms
related to vitamin D and a characterization of possible
differences in the metabolic pathways associated with
25(OH)D levels in obese and non-obese individuals may
help to untangle the relationship between vitamin D,
obesity and cardiometabolic health. Metabolomics, the
comprehensive analysis of measurable metabolites in bio-
logical samples17 (ranging from low-molecular-weight
metabolites to large metabolite complexes18), has pro-
vided new insights into the development of chronic dis-
eases.17 Coupled with traditional epidemiology,
metabolomics offers the potential to study diseases in
humans more comprehensively, and it has already been
successfully applied in the research on diseases such as ath-
erosclerosis, diabetes and obesity.19 So far, however, only
few studies have used metabolomics to examine the link be-
tween vitamin D and health or the metabolic profile associ-
ated with vitamin D, in a limited number of participants
from very selected populations.20,21
In the present study, we used population-based data
to characterize the serum metabolite profile associated
with serum 25(OH)D levels, applying metabolomics
obtained from two platforms based on mass spectrom-
etry (MS) and nuclear magnetic resonance (NMR)
spectroscopy. Furthermore, we aimed to assess possible
differences in the metabolic signature of serum




KORA (Cooperative Health Research in the Region of
Augsburg) is a research platform for population-based surveys
and subsequent follow-up studies in community-dwelling indi-
viduals living in the region of Augsburg in Southern
Germany.22 The present study is based on data from the
KORA F4 study, which was conducted between 2006 and
2008 as a follow-up of the KORA survey S4. A total of 3080 of
the 4261 KORA S4 participants, aged 32–81 years at the time
of the follow-up, took part in KORA F4. More details on the
sampling method are given elsewhere.22,23 The replication was
done in FINRISK 1997, a general population study conducted
to monitor the health of the Finnish population among per-
sons aged 24–74 years at recruitment.24 In total, 8444 indi-
viduals were recruited to represent the working-age
population of five study areas across Finland.24 Both the
KORA F4 study and the FINRISK 1997 study were carried
out in accordance with the Declaration of Helsinki and
approved by the ethics committees of the Bavarian Medical
Association and the National Public Health Institute of
Finland, respectively. Written informed consent was obtained
from all participants.
Data collection
In KORA F4, all participants underwent a standardized med-
ical examination and a computer-aided personal interview at
the study centre, which were conducted by trained examiners
and interviewers. Information on socio-demographic vari-
ables, physical and outdoor activity, smoking behaviour, alco-
hol consumption, comorbidities, self-rated physical
constitution and medication use was obtained in the interview.
Leisure time physical activity in summer and winter25 was
dichotomized in ‘inactive’ (less than 1 h of regular activity per
week in summer and winter) and ‘active’.26 Additionally, the
amount of time participants usually spent outdoors in summer
was recorded.27 Alcohol consumption was calculated from
the intake of beer, wine and spirits during the previous
week.28 Comorbidities included diabetes mellitus (defined by
self-report or current use of antidiabetic drugs) as well as hav-
ing a history of myocardial infarction, stroke or cancer (inpa-
tient treatment, self-reported). Physical constitution was
assessed with the question: ‘How would you rate your current
physical constitution?’. Furthermore, participants were asked
to bring the product packaging of all medications they were
currently using to the study centre. Based on this, intake of
medication during the previous week was recorded through
database-supported computer software.29 Height, weight and
waist circumference were measured in light clothing. Height
was measured to the nearest 0.1 cm, weight to the nearest
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0.1 kg. Waist circumference (WC) was measured at the mid
point between the lower rib and the upper margin of the iliac
crest to the nearest 0.1 cm. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by height in metres
squared. In FINRSIK 1997, standard clinical laboratory meas-
ures were collected, and participants filled out questionnaires
on physical activity. Physical activity was defined by the com-
bination of two questions: ‘How much time do you usually
spend on spare time physical activity?’ (‘active’: 1 h or more)
and ‘At how many times per week do you usually do spare
time physical exercise?’ (‘active’: once per week or more).
Volume of ethanol consumed in the past week was calculated
from beverage-specific questions on consumption of beer,
cider and long drinks, wine and spirits.
Laboratory analyses
In KORA F4, blood samples were collected between 8 a.m.
and 11 a.m. after an overnight fast of at least 8 h. For serum
collection, blood was drawn into serum gel S-Monovette tubes
(Sarstedt, Nu¨mbrecht, Germany), gently inverted two to three
times and rested for 30 min at room temperature to obtain
complete coagulation. Subsequently, the tubes were centri-
fuged for 10 min (2750g at 15C) and the serum was aliquoted
into synthetic straws which were kept for a maximum of 6 h at
4C before storage at 80C until analysis. Total 25(OH)D
concentration in the serum was measured using a chemilumin-
escent immunoassay (LIAISON 25 OH Vitamin D TOTAL
Assay, DiaSorin Inc., Stillwater, USA). The inter-assay coeffi-
cients of variation were 8.7% and 9.1% for target values of
14.7 ng/ml and 47.5 ng/ml, respectively. One participant with
an outlying 25(OH)D concentration (values outside mean6 5
standard deviations) was excluded from the data set. The sea-
son of blood sampling was categorized according to the me-
teorological season. This classification of season has been used
in the KORA F4 study before.27 Serum creatinine concentra-
tion was assessed with a modified Jaffe test (Krea Flex; Dade
Behring), and the estimated glomerular filtration rate was
calculated using the CKD-EPI equation.30 The liver enzyme
gamma-glutamyl-transferase was measured on a Roche/Hitachi
cobas c system, in accordance with the recommendations of the
International Federation of Clinical Chemistry. In FINRSIK
1997, 25(OH)D3 was measured with the ARCHITECT system
(Abbott Laboratories) that uses a chemiluminescent micropar-
ticle immunoassay, which is highly sensitive to natural
25(OH)D3 but less so to synthetic 25(OH)D2.
31
Discovery step in KORA F4; Metabolomics analyses
As described in our previous work,32 metabolite identifica-
tion and quantification in the serum were performed on
two different platforms, based on MS (Metabolon Inc.,
Durham, NC, USA)33,34 and NMR spectroscopy,18,35 re-
spectively. The commercial MS platform is based on two
ultra-high-performance liquid chromatography/tandem
mass spectrometry (UHPLC/MS/MS2) injections and one
gas chromatography/mass spectrometry (GC/MS) injection
per sample. The two UHPLC injections were optimized for
basic and acidic species, respectively (see33 and34 for more
details). The platform provided relative quantification for
a total of 517 compounds, 344 of which could be identified
based on an in-house library of retention index, mass to
charge ratio and fragmentation spectra. The data were pre-
processed and corrected for batch effects as described be-
fore.32 For each metabolite, outlying values (values outside
mean6 4 standard deviations on the log10 scale) were
removed from the data set; 81 metabolites with more than
50% missing values as well as 2 duplicate metabolites were
excluded, leaving 434 metabolites (296 identified and 138
unidentified).
Additionally, an NMR spectroscopy platform18,35,36
was used to obtain quantitative information on 130 metab-
olites and derived measures. Outlier exclusion and de-
tection rate calculations were performed as described for
the MS data; 11 redundant measures representing sums or
differences of other metabolites were excluded, leaving
119 metabolites; And 20 metabolites were covered by both
the MS and the NMR spectroscopy platforms. These me-
tabolites were treated as independent, that is the respective
metabolites from both platforms were included in the ana-
lyses. More detailed considerations on the combined ana-
lysis of metabolites measured on the two metabolomics
platforms are described elsewhere.32
In total, 415 metabolites and derived measures (296
identified metabolites measured with MS as well as 119
metabolites measured with NMR spectroscopy), were used
for the association analyses. These metabolites cover sev-
eral metabolite classes, including constituents of lipopro-
tein subclasses, fatty acids, glycerophospholipids, steroids,
acylcarnitines, bile acid metabolites, amino acids, small
peptides, carbohydrates, xenobiotics, vitamins and nucleo-
tide metabolites. A full list of all metabolites can be found
in the Supplementary Table S1, available as Supplementary
data at IJE online. Throughout the paper, (M) and (N) are
used to indicate metabolites derived from the MS and the
NMR spectroscopy platform, respectively.
Discovery step in KORA F4; Statistical analyses
Data from both metabolomics platforms were available in
a subsample of 1745 participants. In addition to one par-
ticipant with an outlying 25(OH)D concentration, we
excluded: nine participants with more than 20% missing
values in at least one of the metabolomics platforms; eight
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participants who were pregnant or had a fasting duration
of less than 8 h at the time of the examination; and one
participant with missing information in the covariables;
leaving a study population of 1726 participants. For miss-
ing data treatment, we chose multiple imputation by
chained equations.37 The imputation strategy is described
in the Supplementary material, available as Supplementary
data at IJE online. The distribution of the metabolites was
tested against normality before imputation, followed by
transformation where necessary (Supplementary Table S2,
available as Supplementary data at IJE online). Metabolites
were standardized to a mean of zero and a standard deviation
of one. Multiple linear models were used to assess the associ-
ation between each metabolite (outcome) and continuous
25(OH)D levels (predictor). In the main analysis, the models
were adjusted for age, sex, season, WC (continuous), phys-
ical activity, time spent outdoors, smoking status and alcohol
consumption. The Bonferroni method was used to account
for multiple testing. Thus, the adjusted P-value threshold
was set at 1.20 x 104 (0.05/415). To assess possible differ-
ences in the associations of 25(OH)D with the metabolites
between abdominally obese and non-obese subjects, the
main models were stratified by WC status. For this, the cut-
off for abdominal obesity was set at a WC 88 cm in women
and 102 cm in men. Formally, the main models were ex-
tended by interaction terms of the WC status with 25(OH)D
and with each of the other covariables. In these models, the
main effect estimate of 25(OH)D and the sum of the main ef-
fect estimate of 25(OH)D plus the 25(OH)D:WC interaction
effect can be interpreted as the association of 25(OH)D with
the metabolite concentration in the WC reference category
and in the alternative category, respectively. Both effects
were tested using linear hypothesis tests. The adjusted P-
value threshold was set at 6.02 x 1005 (0.05/(2*415)). All
regression analyses were performed with SAS 9.3 (SAS
Institute Inc., Cary, NC, USA).
Replication step in FINRSIK 1997
Metabolite identification and quantification in the serum
was conducted in accordance with KORA F4, in 7503 indi-
viduals (NMR) and 682 individuals (MS), respectively.
The MS data were batch-corrected and scaled for the ana-
lyses. The metabolites were transformed according to the
normal transformations used in KORA F4. All analyses
were performed on the complete observations for the re-
spective metabolite. Data for both NMR and 25(OH)D
were available for a maximum of 6759 participants, and
data for both MS and 25(OH)D for a maximum of 609
participants. The 37 associations with 25(OH)D at
P< 1.20 x 104 (Bonferroni threshold), which were identi-
fied in KORA F4, were replicated in FINRISK 1997. Thus,
the P-value threshold for the replication was set at
1.35 x 103 (0.05/37). The models were adjusted for the
same covariables as in KORA F4, except for time spent
outdoors which was not available in FINRISK 1997, and
season as the FINRISK 1997 samples were all collected
during spring. Furthermore, as the median fasting time was
only 5 h, time from the latest meal in hours was used as a
covariable. For the stratified analyses, WC was categorized
as in KORA F4, and the main model was repeated in both
WC strata. All analyses in FINRISK 1997 were conducted
with RStudio version 0.99.473 that uses R version 3.2.3.
Sensitivity analyses in KORA F4
A number of the metabolites were highly correlated. Joint
testing of clusters instead of single variables helps to avoid
redundancy of the association results and increased power
and reliability in earlier omics studies.38,39 Thus, in add-
ition to the individual metabolite analyses, we examined
eight modules of closely connected metabolites which had
previously been identified by weighted correlation network
analysis.32 The module membership of each metabolite is
given in Supplementary Table S4, available as Supplementary
data at IJE online. Associations between 25(OH)D and the
metabolite modules could not be confirmed in the replication
cohort. As the Metabolon MS platform is untargeted, the
metabolites that were detected in KORA F4 and in
FINRISK 1997 differed to some extent. Thus, the metabol-
ite modules could not be calculated in FINRISK 1997.
More details on the metabolite module analyses are given
in the Supplementary material, available as Supplementary
data at IJE online.
The main models for those metabolites that were associ-
ated with 25(OH)D at P<1 .20 x 104 were re-examined
using vitamin D quartiles. Tests for linear trends across
quartiles were conducted by assigning the median value
within each quartile to the respective quartile and by treat-
ing the assigned median values as a continuous variable.
To assess the impact of WC as an operationalization of
obesity, the main models were re-examined using BMI in-
stead of WC. To assess whether the association between
25(OH)D and the serum metabolites is mediated by para-
thyroid hormone, the main models were additionally ad-
justed for parathyroid hormone. The influence of additional
adjustment for diseases and physical constitution or intake
of medication was examined in additional sensitivity ana-
lyses. In the disease model, the main models were addition-
ally adjusted for diabetes mellitus, history of myocardial
infarction, stroke or cancer, self-rated physical constitution,
estimated glomerular filtration rate (as a measure of kidney
function) and gamma-glutamyl-transferase (as a measure of
liver function). In the medication model, the disease models
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were additionally adjusted for intake of oral contraceptives,
estrogens, diuretics, statins, antiepileptic and oral antidia-
betic medication, corticoids and calcium channel blockers
as well as for angiotensin-converting enzyme inhibitors or
angiotensin antagonists.
Results
The characteristics of KORA F4 and FINRISK 1997 are
shown in Table 1; 25(OH)D levels were relatively low in
both cohorts, with mean values being 15.2 ng/ml (2.0–
46.9 ng/ml) in KORA F4 and 13.8 ng/ml (0.7–32.6 ng/ml)
in FINRISK1997. The distributions of the 25(OH)D levels
in both cohorts are shown in the Supplementary Figure S2a
and b, available as Supplementary data at IJE online.
Individual metabolites associated with 25(OH)D
The results of the main analysis of the discovery step in
KORA F4 for all metabolites are shown in Supplementary
Table S4, available as Supplementary data at IJE online.
Due to the standardization of the metabolites, the b-coeffi-
cients can be interpreted as the difference in metabolite
concentration (in standard deviations) per 1 ng/ml higher
25(OH)D level. For serum triglycerides, for example, every
1 ng/ml higher 25(OH)D level was associated with a 0.0132
standard deviation lower mean triglyceride level. In total,
37 metabolites were associated with 25(OH)D at P<1.
20 x 104 in KORA F4, the majority inversely. For 30 of
these metabolites, the association was replicated in
FINRISK 1997 at P< 1.35 x 103 (Figure 1). Theses me-
tabolites cover: constituents of (very) large subclasses of
very-low-density lipoprotein (VLDL) and small low-
density lipoprotein (LDL) subclasses (all N) as well as
related measures: serum triglycerides [Serum_TG (N)] and
apolipoprotein B [ApoB ((N)]}; total fatty acids ([Tot_FA
(N)]; the x-7 monounsaturated long-chain fatty acid 10-
heptadecenoate (17:1n7) (M); and various measures
which reflect the degree of saturation of fatty acids [all
(N) e.g. monounsaturated fatty acids (MUFA) ((N), x-7,
x-9 and saturated fatty acids (FAw79S) ((N), the average
number of double bonds in a fatty acid chain (DB)_in_
FA (N)]; and the metabolic waste product creatinine (N);
as well as with the urofuran acid 3-carboxy-4-methyl-5-
propyl-2-furanpropanoate (CMPF) (M). For six of the
non-replicated metabolites [the branched chain amino
acid metabolites isoleucine (N), isovalerylcarnitine (M)
and isobutyrylcarnitine (M), palmitoleate (16:1n7) (M),
pyridoxate (M) (a metabolite of vitamin B6 metabolism)
and urea (M)], the effect direction in FINRISK 1997 was
the same as in KORA F4. Only 2-aminobutyrate (M)
showed inconsistent effect directions, being positively
associated with 25(OH)D in KORA F4, and negatively
in FINRISK 1997.
Table 1. Characteristics of the study populations
KORA F4 FR97 NMR FR97 MS
Characteristic N¼1726 N¼6762 N¼609
25(OH)D ng/ml 15.2 (7.5)* 13.8 (5.9)* 14.1 (6.0)*
Age years 60.8 (8.8)* 47.8 (13.0)* 50.7 (13.7)*
Sex male 834 (48.3) 3352 (49.6) 381 (62.6)
female 892 (51.7) 3410 (50.4) 228 (37.4)
Waist circumference cm 95.6 (14.1)* 87.9 (13.4)* 90.6 (13.2)*
Waist circumference statusa abdominally obese 857 (49.7) 1665 (24.6) 172 (28.2)
abdominally non-obese 869 (50.3) 5097 (75.4) 437 (71.8)
Time spent outdoors in summer h/day 4.4 (2.5)* – –
Season December–February 550 (31.9) – –
March–May 408 (23.6) – –
June–August 269 (15.6) – –
September–November 499 (28.9) – –
Physical activity active 995 (57.7) 1903 (28.1) 161 (26.4)
inactive 731 (42.3) 4859 (71.9) 448 (73.6)
Alcohol consumption g/day 15.5 (20.4)* 9.3 (16.9)* 9.9 (16.8)*
Smoking status never 730 (42.3) 3591 (53.1) 305 (50.0)
former 743 (43.1) 1548 (22.9) 141 (23.2)
current 253 (14.6) 1623 (24.0) 163 (26.8)
Numbers indicate N (%) unless marked otherwise; *numbers indicate mean (standard deviation).
WC, waist circumference; 25(OH)D, 25-hydroxyvitamin D.
aAbdominally obese: WC 88 cm in women / 102 cm in men; abdominally non-obese: WC< 88 cm in women /< 102 cm in men.
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Figure 1. Individual metabolites associated with 25(OH)D in KORA F4 and FINRISK 1997. b-coefficients (standardized), 95% confidence intervals and
P-values of the 37 metabolites associated with 25(OH)D (P-value threshold: 1.20 x104) in KORA F4 (square). Of these, 30 associations were replicated
in FINRISK 1997 (diamond) at P<1.35 x 103. Main models: adjusted for age, sex, season (KORA F4 only), WC (continuous), physical activity, time out-
doors (KORA F4 only), smoking status and alcohol consumption.
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Individual metabolite associations in abdominally
obese and non-obese participants
In general, the associations between 25(OH)D and the 37
metabolites observed at P< 1.20 x 104 in the main ana-
lyses were similar in abdominally obese and non-obese par-
ticipants, both in KORA F4 (Figure 2) and in FINRISK
1997. Exceptions in FINRISK 1997 were 2-aminobutyrate
(M) and urea (M). For some metabolites, the strength of
the association with 25(OH)D appeared to differ accord-
ing to waist circumference status. For instance, the positive
association of 25(OH)D with some measures of fatty acid
polyunsaturation and with CMPF (M) seemed to be stron-
ger in abdominally obese participants in both cohorts.
However, none of the interaction terms in KORA F4 had a
P-value< 6.02 x 1005. In non-obese participants, 10 me-
tabolites were inversely associated with 25(OH)D at
P< 6.02 x 1005 in KORA F4, eight of which were repli-
cated in FINRISK 1997: small LDL particles, total lipids in
small LDL (S_LDL_L) (N)) summary measures of fatty
acids (Tot_FA) (N), MUFA (N), FAw79S (N), CH3 groups
of mobile lipids (MobCH3) (N) and total phosphoglycer-
ides, phosphatidylcholines. In abdominally obese partici-
pants, eight metabolites were associated with 25(OH)D at
P< 6.02 x 1005 in KORA F4, six of which were replicated
in FINRISK 1997: the average number of methylene
groups per double bond (CH2_DB_ratio) (N) was inversely
associated, DB_in_FA (N), the ratio of bisallylic groups to
double bonds (Bis_DB_ratio) (N), the ratio of bisallylic
groups to total fatty acids (Bis_FA_ratio) (N), creatinine
(N) and CMPF (M) were positively associated.
Sensitivity analyses in KORA F4
Additional characteristics of KORA F4 for the sensitivity
analyses are shown in the Supplementary Table S5 (avail-
able as Supplementary data at IJE online) and a more de-
tailed description of the results of the sensitivity analyses is
given in the Supplementary material as well. Briefly,
25(OH)D levels were inversely associated with two of the
metabolite modules: M1, which is mainly represented by
total triglycerides, constituents of all VLDL subclasses and
measures of primarily saturated and monounsaturated
fatty acids (P¼0.00002); and M3, which is mainly repre-
sented by constituents of LDL and intermediate density
lipoprotein (IDL) subclasses, measures of serum cholesterol
and Apo B (P¼0.00332) (Supplementary Table S6, avail-
able as Supplementary data at IJE online). For the majority
of the 37 metabolites that were associated with 25(OH)D
at P< 1.20 x 104, a linear relationship seems likely
(Supplementary Figure S3, available as Supplementary
data at IJE online) and the tests for linear trends were
significant at P< 1.35 x 103 for all 37 metabolites except
Free_C (N) (data not shown). Using BMI instead of WC
(Supplementary Figure S4, available as Supplementary data
at IJE online) to operationalize obesity as well as additional
adjustment for parathyroid hormone (Supplementary Table
S7, available as Supplementary data at IJE online) resulted
in only marginal changes in the effect estimates. Additional
adjustment for health status (Supplementary Figure S6) and
intake of medication (Supplementary Figure S7, available as
Supplementary data at IJE online) resulted in additional
constituents of VLDL subclasses being associated with
25(OH)D at P< 1.20 x 104, whereas the association with
isobutyrylcarnitine (M), isovalerylcarnitine (M), pyridoxate
(M), creatinine (N) and urea (M) disappeared.
Discussion
In the present study, we used serum metabolomics data ob-
tained from two analytical platforms to characterize the
metabolic profile associated with serum 25(OH)D levels in
1726 participants of the population-based KORA F4
study. In total, 37 of the 415 examined metabolites were
associated with 25(OH)D after Bonferroni correction. Of
these, 30 associations were replicated in the population-
based FINRISK 1997 study. These metabolites include
constituents of (very) large VLDL and small LDL sub-
classes and related measures like serum triglycerides and
ApoB, various summary measures of fatty acids and fatty
acid polyunsaturation as well as CMPF. The observed as-
sociations were independent of waist circumference and
were generally similar in abdominally obese and non-obese
participants. Furthermore, they persisted after adjustment
for parathyroid hormone, health status and intake of a var-
iety of medications.
To our knowledge, this is the first study in which the
serum metabolite profile associated with 25(OH)D levels
is examined in such a comprehensive way. In a previ-
ous study, an NMR spectroscopy-based approach was
used to identify a metabotype responsive to vitamin D sup-
plementation with regard to markers of the metabolic
syndrome.20 In the identified responsive metabotype, a
4-week vitamin D supplementation reduced VLDL and
LDL, glucose and glycerol-phosphocholine in the nine par-
ticipants of the intervention group.20 In another study,
Finkelstein and colleagues examined the association be-
tween 25(OH)D levels and the serum metabolite profile
(measured by Metabolon Inc.) in 30 pregnant adoles-
cents.21 Using a hierarchical mixture model, they identified
11 metabolites which were associated with 25(OH)D lev-
els20 ng/ml: higher pyridoxate, bilirubin, xylose and
cholate levels, as well as lower leukotrienes, 1,2-propane-
diol, azelate, undecanedioate, sebacate, inflammation-
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Figure 2. Individual metabolite associations in abdominally obese and non-obese participants in KORA F4. b-coefficients (standardized), 95% confi-
dence intervals and P-values of the 37 metabolites associated with 25(OH)D from the main models for abdominally obese (circle) and non-obese (tri-
angle) participants. In addition, 25(OH)D was associated with glucose (N) (b¼0.0204, P-value¼ 0.00004) in abdominally obese participants and with
3-methyl-2-oxovalerate (M) (b¼0.0162, P-value¼ 0.00005) in non-obese participants (P-value threshold was set at 6.02 x 1005).
International Journal of Epidemiology, 2016, Vol. 45, No. 5 1477
associated complement component 3 peptide
(HWESASXX) and piperine.21 None of these metabolites
was associated with 25(OH)D in the present study. This
discrepancy may be due to differences in the study popula-
tions (middle-aged to older adults with pregnant partici-
pants being excluded, vs pregnant adolescents).
In the present study, higher 25(OH)D levels were asso-
ciated with lower levels of serum triglycerides, constituents
of (very) large VLDL subclasses and small LDL particles.
Furthermore, levels of Apo B, the primary apolipoprotein
in atherogenic lipoprotein particles (VLDL, IDL and LDL)
and thus an estimate of total atherogenic particle num-
ber,40 were lower with higher 25(OH)D levels. High levels
of triglycerides, VLDL and LDL, especially small LDL, are
important risk factors for atherosclerosis and coronary
heart disease.41 Atherogenic dyslipidaemia, a triad of
increased concentrations of small, dense LDL particles,
decreased high-density lipoprotein particles and increased
triglycerides, is a characteristic of type 2 diabetes, insulin
resistance and the metabolic syndrome and an important
risk factor for myocardial infarction and cardiovascular
disease.42 An underlying mechanism of the inverse associ-
ation between 25(OH)D levels and atherogenic lipids
observed in the present study might be the relationship be-
tween vitamin D and lipoprotein lipase (LPL), an enzyme
that catalyses the lipolysis of triglycerides in lipoproteins
into two free fatty acids and one monoacylglycerol43 and
thereby converts VLDL to IDL and then to LDL.41 Serum
levels of 25(OH)D were found to be positively associated
with LPL concentrations in a cohort of Chinese adults43
and 1,25(OH)2D was found to increase lipoprotein lipase
expression and activity in vitro.44 Higher 25(OH)D levels
were associated with lower levels of total fatty acids as
well as with an increased degree of polyunsaturation of
fatty acids (e.g. with a higher ratio of bisallylic groups to
total fatty acids45) in the present study. In part, this associ-
ation is likely to reflect diet quality. In a recent clinical
trial, a healthy diet characterized by increased intake of
whole grain products, fish and bilberries, resulted in an
increased degree of polyunsaturation of plasma fatty
acids.45 Interestingly, however, this healthy diet in particu-
lar increased x-3 fatty acids, whereas in our study,
25(OH)D was not associated with total x-3 fatty acids
(b¼ 0.0018, P-value¼ 0.62) or single x-3 fatty acids.
Thus, the positive association between 25(OH)D and fatty
acid polyunsaturation observed in the present study may
be more than a simple representation of diet quality. In
participants of the Cardiovascular Risk in Young Finns
Study, measures of increased fatty acid polyunsaturation
were found to be associated with a decreased risk for
6-year high intima-media thickness progression and low
6-year carotid distensibility prevalence, both markers of
subclinical atherosclerosis.46 Furthermore, the risk for low
6-year carotid distensibility prevalence was increased with
higher levels of apolipoprotein B.46
Of note, the majority of the metabolites associated with
25(OH)D levels in the present study were also associated
with weight change in our previous work.32 As a reduction
in BMI is associated with increased levels of serum
25(OH)D,47 this speaks in favour of a confounding effect
of obesity. However, the associations observed in the pre-
sent study were independent of waist circumference or
BMI and were generally similar in abdominally obese and
non-obese participants. In fact, the association with a clus-
ter of metabolites constituting atherogenic lipids (metabol-
ite module M3) was only found in non-obese participants.
Thus, the associations observed in the present study are un-
likely to merely reflect pathomechanisms associated with
obesity.
Our study is among the first to use a metabolomics ap-
proach to examine 25(OH)D levels, and the results of this
study are based on large study populations from phenotyp-
ically well-characterized population-based cohorts.
However, several limitations need to be mentioned, of
which the greatest is the cross-sectional design. Although
we did adjust our models for a variety of socioeconomic,
lifestyle and health-related variables, cross-sectional find-
ings are prone to residual confounding. Specifically, associ-
ations with 25(OH)D might in fact reflect associations
which are mediated by other bioactive components
induced by ultraviolet radiation, such as nitric oxide.48 In
male mice for example, long-term ultraviolet radiation,
which had no influence on serum 25(OH)D levels, sup-
pressed measures of the metabolic syndrome such as chol-
esterol levels.48 The observed associations might further be
the result of a healthy lifestyle involving increased sun ex-
posure due to more frequent outdoor physical activity and
a healthy diet rich in vitamin D, which was not sufficiently
captured by the covariables in our models. In particular,
the measures of physical activity were quite imprecise and
diet quality was not assessed in the KORA F4 study. The
latter aspect might also be reflected in our results by the
positive association of 25(OH)D with CMPF, which has
recently been identified as a highly specific biomarker for
fatty fish intake.49 The association with CMPF was consid-
erably stronger in abdominally obese participants. Given
that obese individuals are less likely to be exposed to sun-
light, due to less involvement in outdoor activities and due
to different clothing habits,11 their major source of vitamin
D might be diet rather than exposure to sunlight. Due to
the cross-sectional design, we cannot draw conclusions on
the causality or direction of the observed associations.
Thus, the inverse associations between 25(OH)D and the
metabolites reflective of a cardiometabolic risk profile
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might indicate an underlying disease, for which a low
25(OH)D status merely serves as a biomarker.50 The
KORA F4 participants are relatively healthy and the asso-
ciations between 25(OH)D and the metabolites persisted
after adjustment for health status and intake of a variety of
medications. However Mendelian randomization studies,
which should be unaffected by confounding and reverse caus-
ation,51 provide ambiguous results on the relationship be-
tween vitamin D and cardiometabolic health. Whereas some
results support a causal effect of higher vitamin D levels on a
more favourable lipid profile,52 other studies question the
role of 25(OH)D in the aetiology of obesity53 or type 2 dia-
betes,54 ischaemic heart disease55 and cardiovascular mortal-
ity56. Furthermore, levels of 25(OH)D were relatively low in
both cohorts. In KORA F4, this may be partly attributable to
the use of the DiaSorin LIAISON assay. This assay has a
high variance, especially at high concentrations, and com-
pared with the gold-standard liquid chromatography-tandem
mass spectrometry, it was found to underestimate 25(OH)D
levels (mean bias: -7.2 ng/ml).57 A linear trend was observed
for the association between 25(OH)D and the metabolites,
but conclusions for 25(OH)D levels outside the observed
range should still be drawn with care.
In conclusion, using serum metabolomics obtained from
two MS- and NMR-spectroscopy-based platforms, we
observed that higher serum 25(OH)D levels were associ-
ated with a metabolic profile characterized by lower con-
centrations of atherogenic lipids and a higher degree of
fatty acid polyunsaturation. These associations, which re-
flect the well-observed relationship between 25(OH)D de-
ficiency and cardiometabolic diseases, were independent of
waist circumference and, in general, similar in abdominally
obese and non-obese individuals. Therefore, our results in-
dicate that the relationship between vitamin D deficiency
and cardiometabolic diseases is unlikely to merely reflect
pathomechanisms related to obesity. However, additional
longitudinal studies are needed to validate these results be-
fore further conclusions on the biological mechanisms
linked to vitamin D can be drawn.
Supplementary Data
Supplementary data are available at IJE online.
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